Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: estimated 300 to confirmed 346v17
  2. Primary and study completion dates: Dec 2024 to Dec 2027v16
  3. Primary and study completion dates: Dec 2023 to Dec 2024v15
  4. Re-verified, no change to tracked fieldsv14
  5. Primary and study completion dates: Dec 2022 to Dec 2023v13
Show 11 earlier versionsHide 11 earlier versions
  1. Primary and study completion dates: Dec 2021 to Dec 2022v12
  2. Re-verified, no change to tracked fieldsv11
  3. Primary and study completion dates: Dec 2020 to Dec 2021v10
  4. Re-verified, no change to tracked fieldsv9
  5. Primary and study completion dates: Dec 2019 to Dec 2020v8
  6. Primary and study completion dates pushed to Dec 2019v7
  7. Primary completion date: Dec 2016 to Dec 2017
    • Study completion date: Dec 2016 to Dec 2018
    v6
  8. Collaborators revised (2)v5
  9. Primary and study completion dates: Dec 2014 to Dec 2016v4
  10. Primary and study completion dates: Dec 2013 to Dec 2014v3
  11. Trial status: Recruiting to Active, Not Recruitingv2 Show 5 more changesShow less
    • Primary and study completion dates: Dec 2013
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
    • Collaborators revised (2)
    • Study arms: 0 to 1
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to measure the oxygen content and interstitial fluid pressure in cervix cancer patients. Tumour oxygen content and internal pressure of tumours may be an important factor that influences the effectiveness of radiotherapy and other treatments.
Trial Details
NCT Number NCT00188539
Lead Sponsor University Health Network, Toronto
Collaborators: Canadian Cancer Trials Group, Princess Margaret Hospital, Canada
Conditions
(from sponsor)		 Cervix Neoplasms
Related terms Uterine Cervical Neoplasms
Enrollment 346 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov